Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)

The summary for the Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01): The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests research applications seeking support for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans. It also includes bioanalytical assay development and validation, laboratory-scale and scale-up manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.
Federal Grant Title: Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)
Federal Agency Name: National Institutes of Health
Grant Categories: Environment Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-16-331
Type of Funding: Cooperative Agreement
CFDA Numbers: 324027, 324028, 324026, 324025, 324004
CFDA Descriptions: Environmental Health; Arthritis, Musculoskeletal and Skin Diseases Research; Extramural Research Programs in the Neurosciences and Neurological Disorders; Vision Research
Current Application Deadline: Sep 11, 2018
Original Application Deadline: Sep 11, 2018
Posted Date: Jun 15, 2016
Creation Date: Jun 15, 2016
Archive Date: Oct 12, 2018
Total Program Funding:
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Small businesses
For profit organizations other than small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Special district governments
Native American tribal organizations (other than Federally recognized tribal governments)
County governments
Native American tribal governments (Federally recognized)
State governments
Independent school districts
City or township governments
Public housing authorities/Indian housing authorities
Public and State controlled institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-16-331.html
Grant Announcement Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021 FederalGrants.com